文献速递脑血管病

房颤卒中后早期使用阿哌沙班:AREST试验结果

Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial.
PubMed 文献 · Stroke · 2021-02-25

AREST是一项开放标签随机对照试验,比较房颤相关TIA或小/中型缺血性卒中后早期使用阿哌沙班与延迟使用华法林的安全性。试验因指南更新提前终止,结果显示阿哌沙班在复发性卒中/TIA、死亡、致命性卒中及症状性出血等方面数值上均低于华法林,但差异无统计学意义。早期抗凝似乎不损害患者安全,但疗效有待更大规模试验确定。

要点

  • 房颤相关TIA或小/中型缺血性卒中后早期启动阿哌沙班未显示安全性劣于延迟华法林。
  • 阿哌沙班组复发性卒中/TIA、死亡及症状性出血发生率数值上均低于华法林组。
  • 早期抗凝的潜在疗效尚需更大规模关键试验验证。

核心结论

  • 房颤相关TIA或小/中型缺血性卒中后早期启动抗凝似乎不损害患者安全。
  • 早期抗凝的潜在疗效仍需更大规模关键试验确定。

研究设计与样本

  • AREST为开放标签随机对照试验,比较早期阿哌沙班与延迟华法林用于房颤相关TIA或缺血性卒中患者。
  • 阿哌沙班启动时机:TIA第0-3天,小型AIS(<1.5 cm)第3-5天,中型AIS(≥1.5 cm,除外全皮质 territory)第7-9天。
  • 华法林启动时机:TIA后1周或AIS后2周,按1:1随机分组。
  • 试验因国家指南焦点更新推荐直接口服抗凝药优于华法林而提前终止。

主要发现

  • 复发性卒中/TIA发生率阿哌沙班组14.6% vs 华法林组19.2%(P=0.78)。
  • 死亡率阿哌沙班组4.9% vs 华法林组8.5%(P=0.68)。
  • 致命性卒中发生率阿哌沙班组2.4% vs 华法林组8.5%(P=0.37)。
  • 症状性出血发生率阿哌沙班组0% vs 华法林组2.1%。
  • 主要复合终点(致命性卒中、复发性缺血性卒中或TIA)阿哌沙班组17.1% vs 华法林组25.5%(P=0.44)。

临床怎么用

  • 对房颤相关TIA或小/中型缺血性卒中患者,可考虑早期启动阿哌沙班抗凝而不明显增加安全风险。
  • 早期抗凝的疗效优势尚未确立,临床决策需结合指南和个体化评估。

局限性

  • 试验因指南更新提前终止,样本量可能不足以检测统计学显著差异。
  • 开放标签设计可能引入偏倚。
  • 早期抗凝的疗效需更大规模关键试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: It is unknown when to start anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF). Early anticoagulation may prevent recurrent infarctions but may provoke hemorrhagic transformation as AF strokes are typically larger and hemorrhagic transformation-prone. Later anticoagulation may prevent hemorrhagic transformation but increases risk of secondary stroke in this time frame. Our aim was to compare early anticoagulation with apixaban in AF patients with stroke or transient ischemic attack (TIA) versus warfarin administration at later intervals. METHODS: AREST (Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation) was an open-label, randomized controlled trial comparing the safety of early use of apixaban at day 0 to 3 for TIA, day 3 to 5 for small-sized AIS (<1.5 cm), and day 7 to 9 for medium-sized AIS (≥1.5 cm, excluding full cortical territory), to warfarin, in a 1:1 ratio at 1 week post-TIA, or 2 weeks post-AIS. RESULTS: Although AREST ended prematurely after a national guideline focused update recommended direct oral anticoagulants over warfarin for AF, it revealed that apixaban had statistically similar yet generally numerically lower rates of recurrent strokes/TIA (14.6% versus 19.2%, P=0.78), death (4.9% versus 8.5%, P=0.68), fatal strokes (2.4% versus 8.5%, P=0.37), symptomatic hemorrhages (0% versus 2.1%), and the primary composite outcome of fatal stroke, recurrent ischemic stroke, or TIA (17.1% versus 25.5%, P=0.44). One symptomatic intracerebral hemorrhage occurred on warfarin, none on apixaban. Five asymptomatic hemorrhagic transformation occurred in each arm. CONCLUSIONS: Early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety. Potential efficacy of early initiation of anticoagulation remains to be determined from larger pivotal trials. Registration: URL: https://www.clinicaltrials.gov/; Unique identifier: NCT02283294.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Labovitz AJ, Rose DZ, Fradley MG, et al. Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial. Stroke. 2021. PMID: 33626904. doi:10.1161/STROKEAHA.120.030042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。